Dopaminergic network differences in human impulsivity

Science

Volumn 329, Issue 5991, 2010, Pages 532-

  Buckholtz, Joshua W ^a,b   Treadway, Michael T ^a   Cowan, Ronald L ^a   Woodward, Neil D ^a   Li, Rui ^a   Ansari, M Sib ^a   Baldwin, Ronald M ^a   Schwartzman, Ashley N ^a   Shelby, Evan S ^a   Smith, Clarence E ^a   Kessler, Robert M ^a   Zald, David H ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE;

BIOCHEMISTRY; BRAIN; LIGAND; PUBLIC HEALTH; TOMOGRAPHY;

CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; HUMAN; IMPULSIVENESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; AUTORECEPTORS; BENZAMIDES; CORPUS STRIATUM; DEXTROAMPHETAMINE; DOPAMINE; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; LIGANDS; MALE; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TEGMENTUM MESENCEPHALI; VENTRAL TEGMENTAL AREA; YOUNG ADULT;

EID: 77955113598     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1185778     Document Type: Short Survey

References (10)

1. L. Malloy-Diniz, D. Fuentes, W. B. Leite, H. Correa, A. Bechara, J. Int. Neuropsychol. Soc. 13, 693 (2007).
2. A. Verdejo-Garcia, A. J. Lawrence, L. Clark, Neurosci. Biobehav. Rev. 32, 777 (2008).
3. E. S. Barratt, M. S. Stanford, L. Dowdy, M. J. Liebman, T. A. Kent, Psychiatry Res. 86, 163 (1999).
4. R. Cools, R. A. Barker, B. J. Sahakian, T. W. Robbins, Neuropsychologia 41, 1431 (2003).
5. J. W. Dalley et al., Science 315, 1267 (2007).
6. Materials and methods are available as supporting material on Science Online.
7. M. Santiago, B. H. Westerink, Eur. J. Pharmacol. 204, 79 (1991).
8. N. M. Lambert, M. McLeod, S. Schenk, Addiction 101, 713 (2006).
9. M. L. Zilberman, H. Tavares, N. el-Guebaly, BMC Psychiatry 3, 1 (2003).
10. This research was funded by the National Institute on Drug Abuse (R01DA019670-04).